STAR HEALTH AND ALLIED INSURANCE

RESULT UPDATE

KEY DATA

Rating	BUY
Sector relative	Neutral
Price (INR)	427
12 month price target (INR)	490
52 Week High/Low	648/327
Market cap (INR bn/USD bn)	251/2.9
Free float (%)	36.6
Avg. daily value traded (INR mn)	735.3

SHAREHOLDING PATTERN

	Jun-25	Mar-25	Dec-24
Promoter	58.04%	57.67%	57.68%
FII	13.89%	18.69%	17.51%
DII	21.08%	15.44%	16.49%
Pledge	0%	0%	0%

FINANCIALS (INR mn)

Year to March	FY25A	FY26E	FY27E	FY28E
GDPI	167,162	179,565	210,316	239,826
NEP	148,222	167,293	185,891	210,456
U/W profit /(loss)	(3,785)	(793)	139	1,503
PAT	6,459	8,519	11,457	13,842
EPS Growth (%)	(23.9)	31.9	34.5	20.8
Combined ratio (%)	101.1	99.7	98.1	97.2
RoAE (%)	9.7	11.8	14.0	14.7
Adj. P/E (x)	39.1	29.7	22.0	18.3
P/ABV (x)	3.6	3.2	2.8	2.4

CHANGE IN ESTIMATES

	Revised estimates		% Revision	
Year to March	FY26E	FY27E	FY26E	FY27E
NEP	171,429	197,277	(1.0)	(1.5)
CoR	99.7	98.1	42bp	30bp
U/w profit	(793)	139	192.1	(77.0)
APAT	8,519	11,457	(3.2)	(2.6)

PRICE PERFORMANCE



Encouraging growth in fresh business

Adjusted for 1/n accounting, Q1 GWP grew 13.2% YoY (reported growth just 3.4% YoY). Loss ratios stayed elevated at 69.5% (+197bp YoY/-31bp QoQ) as price hikes are yet to flow in. CoR rose sharply by 301bp YoY to 102.2% (adjusted for 1/n, CoR up 160bp YoY to 100.8%). Underwriting profit plunged 48.9% YoY to INR717mn (Ind-AS: INR160mn) while APAT came in at INR2.6bn (Ind-AS: INR4.38bn).

We expect corrective actions in the form of selective underwriting and repricing along with scale benefits to reduce CoRs. We are tweaking estimates leading to FY26E/27E/28E APAT decline of 3.2%/2.6%/4% and TP of INR490 (from INR500). At the CMP, the stock is trading at a cheap FY27E P/E of 21.3x and P/investment book of 1.1x; retain 'BUY'.

Fresh business growth sustains

Q1 GWP grew 3.7% YoY/-29.8% QoQ to INR36.1bn. Adjusted for 1/n accounting, Q1 GWP grew 13.2% YoY versus reported growth of just 3.4%. NEP improved 11.9% YoY to INR39.3bn as 1/n accounting does not affect earned premium. We estimate fresh business in GWP mix improved to 24.8% in Q1FY26 (-18bp YoY/134bp QoQ). Management said less than 15% of fresh business is port-in–indicating lower loss ratios in the waiting period. They also said the long-term business as a proportion of fresh business is high at 30%, which we believe shall lead to enhanced renewal rates over FY27E–29E. In Q1FY26, agency/digital business clocked fresh business growth of 16%/73% YoY (FY25: 16% for agency). Management said directly sourced business in digital channel was 70%—this shall lead to lower acquisition costs in future.

Expenses and investment income surge

In Q1FY26, loss ratios continued to stay elevated at 69.5% (97bp YoY/-31bp QoQ) as management clarified that customers continue to increasingly use insurance. Moreover, management said that for Q1FY26, retail/group claim ratio was 68.5%/85.1% (+160bp/710bp YoY). Management has hiked prices by 8–12% in ~65% of the retail portfolio and is now more selective in underwriting group business. The impact of these measures is likely to flow in net earned premium and reduce loss ratios in H2FY26E. Commission ratio rose 116bp YoY to 14.7% mainly due to a change to 1/n accounting and higher share of sale of long-term policy in fresh business. For Q1FY26, CoR increased 301bp YoY to 102.2% (adjusted for 1/n, CoR increased 160bp YoY to 100.8%). Strong markets in Q1 supported investment income (-0.3% YoY/3.4% QoQ) to INR2.95bn at yield of 6.5% (-102bp YoY) despite the company not booking capital gains in Q1 (~17% of investment book is non-fixed income). This resulted in APAT of INR2.6bn (-17.7% YoY).

Financials

Year to March	Q1FY26	Q1FY25	% Change	Q4FY25	% Change
NEP	39,383	35,203	7.9	37,983	3.7
Combined ratio(%)	102.2	99.2	301bp	99.2	297bp
Underwriting profit/(loss)	717	1,404	(48.9)	(2752)	NM
APAT	2,625	3,189	(17.7)	5	NM

Madhukar Ladha
madhukar.ladha@nuvama.com

Mahrukh Adajania
Mahrukh.Adajania@nuvama.com

Financial Statements

Income Statement (INR mn)

Year to March	FY25A	FY26E	FY27E	FY28E
GDPI	**167,162**	**179,565**	**210,316**	**239,826**
GWP	167,814	180,078	210,316	225,436
Net earned premium (NEP)	**148,222**	**167,293**	**185,891**	**210,456**
Total claims incurred	104,194	115,388	126,963	142,899
Total commission	22,407	25,291	29,000	33,365
Operating expenses	25,406	27,407	29,789	32,688
Underwriting profit/(loss)	**(3,785)**	**(793)**	**139**	**1,503**
Investment income	12,853	12,730	15,732	17,564
Provisions (Other than taxation)	2	0	16	18
Expenses of management	510	190	200	210
Operating profit	**8,556**	**11,747**	**15,655**	**18,840**
Interest expense	0	400	400	400
Other income	55	52	55	57
Profit before tax	8,611	11,399	15,310	18,498
Taxes	2,152	2,881	3,854	4,656
APAT	**6,459**	**8,519**	**11,457**	**13,842**
Extraordinary	0	0	0	0
RPAT	**6,459**	**8,519**	**11,457**	**13,842**

Balance Sheet (INR mn)

Year to March	FY25A	FY26E	FY27E	FY28E
Share capital	5,878	5,878	5,878	5,878
Reserve and surplus	64,359	72,517	83,974	97,816
Total shareholders fund	**75,821**	**84,124**	**95,740**	**109,759**
Fair value change account	885	1,029	1,188	1,366
Borrowings	4,700	4,700	4,700	4,700
Total source of funds	**207,846**	**224,685**	**252,376**	**287,438**
Investments	178,984	199,667	224,092	255,400
Net block	1,849	2,234	2,361	2,583
Goodwill	0	0	0	0
Deferred tax asset	3,512	800	800	800
Cash & bank balance	6,684	5,521	6,134	6,945
Advances & other assets	16,817	16,463	18,989	21,710
Total current assets	**23,501**	**21,984**	**25,123**	**28,655**
Current liabilities	26,480	32,725	36,141	40,450
Provisions	90,814	95,143	106,529	121,510
Total current liabilities	**132,025**	**140,561**	**156,636**	**177,679**
Net current assets	**23,501**	**21,984**	**25,123**	**28,655**
Total assets	**207,846**	**224,685**	**252,376**	**287,438**

Key Ratios (%)

Year to March	FY25A	FY26E	FY27E	FY28E
Growth				
GDPI growth	9.6	7.4	17.1	14.0
GWP growth	10.0	7.3	16.8	7.2
NEP growth	14.6	12.9	11.1	13.2
Operating profit growth	(23.9)	32.6	34.4	20.9
APAT growth	(23.6)	31.9	34.5	20.8
FDEPS growth	(23.9)	31.9	34.5	20.8
Effeciency				
Claims ratio	70.3	69.0	68.3	67.9
Commission ratio	14.4	14.8	14.7	14.8
Expenses ratio	16.7	16.1	15.2	14.6
Combined ratio	101.1	99.7	98.1	97.2
Underwriting profit margin (%)	(2.6)	(0.5)	0.1	0.7
Investment yield	7.6	7.6	7.5	7.4
Investment Income/NEP (%)	8.7	7.6	8.5	8.3
EBIT margin	5.8	7.0	8.4	9.0
PAT margin	4.4	5.1	6.2	6.6
ROE	9.5	11.3	13.4	14.1
Adjusted ROE	9.7	11.8	14.0	14.7
Claims os/ NEP (x)	0.1	0.1	0.1	0.1
Technical reserves/NEP (x)	0.7	0.6	0.6	0.7
Investment leverage (x)	2.5	2.5	2.5	2.4

Source: Company and Nuvama estimates

Per Share Data

Year to March	FY25A	FY26E	FY27E	FY28E
FDEPS (INR/sh)	10.9	14.3	19.3	23.3
DPS (INR/sh)	0	0	0	0
BV (INR/sh)	120.6	134.7	154.4	178.1

Valuation at CMP

Year to March	FY25A	FY26E	FY27E	FY28E
P/GWP	1.5	1.3	1.2	1.0
Adj. P/E	39.1	29.7	22.0	18.3
Adj. P/E (Adj for FV change)	38.5	28.4	21.3	17.6
P/ABV	3.6	3.2	2.8	2.4
Dividend Yield (%)	0	0	0	0

Valuation at TP

Year to March	FY25A	FY26E	FY27E	FY28E
P/GWP	1.7	1.6	1.4	1.2
Adj. P/E	45.1	34.2	25.4	21.0
Adj. P/E (Adj for FV change)	44.4	32.8	24.5	20.3
P/ABV	4.1	3.7	3.2	2.8
Dividend Yield (%)	0	0	0	0

Exhibit 1: NEP expands 11.9% YoY; loss ratio increases 197bp YoY to 69.5% dragging profits down 17.7% YoY

(INR mn)	Q1FY26	Q1FY25	YoY(%/bp)	Q4FY25	QoQ(%/ bp)	FY25	FY26E	FY27E	FY28E
NWP	**34,574**	**31,702**	**9.1**	**48,196**	**(28.3)**	**155,252**	**171,429**	**197,277**	**225,436**
NEP	**39,383**	**35,203**	**11.9**	**37,983**	**3.7**	**148,222**	**167,293**	**185,891**	**210,456**
Claims Incurred (net)	27,390	23,789	15.1	26,301	4.1	104,194	(115,388)	(126,963)	(142,899)
Commission (net)	5,078	4,288	18.4	7,598	(33.2)	22,407	(25,291)	(29,000)	(33,365)
Operating expenses	6,197	5,722	8.3	6,836	(9.3)	25,406	(27,407)	(29,789)	(32,688)
Premium deficiency	-	-	NM	-	NM	-	-	-	-
Underwriting profit/(loss)	**717**	**1,404**	**(48.9)**	**(2,752)**	**(126.1)**	**(3,785)**	**(793)**	**139**	**1,503**
Investment Income	2,950	2,958	(0.3)	2,853	3.4	12,853	12,730	15,732	17,564
Provisions (Other than taxation)	-	0	(100.0)	4	(100.0)	5	-	(16)	(18)
Shareholders' expenses	152	109	39.0	146	3.6	508	(190)	(200)	(210)
Operating profits	**3,515**	**4,252**	**(17.3)**	**(49)**	**NM**	**8,556**	**11,747**	**15,655**	**18,840**
Interest Expense	-	-	NM	-	NM	-	(400)	(400)	(400)
Other income	5	10	(49.5)	41	(87.7)	55	52	55	57
PBT	**3,520**	**4,262**	**(17.4)**	**(9)**	**NM**	**8,611**	**11,399**	**15,310**	**18,498**
Tax	895	1,072	(16.5)	(14)	NM	2,152	(2,881)	(3,854)	(4,656)
APAT	**2,625**	**3,189**	**(17.7)**	**5**	**NM**	**6,459**	**8,519**	**11,457**	**13,842**
Extraordinary	-	-	NM	-	NM	-	-	-	-
RPAT	**2,625**	**3,189**	**(17.7)**	**5**	**NM**	**6,459**	**8,519**	**11,457**	**13,842**
Ratios (%)									
Claims Ratio	69.5	67.6	197bp	69.2	31bp	70.3	69.0	68.3	67.9
Commission Ratio	14.7	13.5	116bp	15.8	(108)bp	14.4	14.8	14.7	14.8
Expense Ratio	17.9	18.1	(13)bp	14.2	374bp	16.4	16.0	15.1	14.5
Combined Ratio	**102.2**	**99.2**	301bp	**99.2**	297bp	**101.1**	**99.7**	**98.1**	**97.2**

Source: Company, Nuvama Research

Exhibit 2: Retail health GWP expands 16.2% YoY to INR37.1bn despite 1/n recognition

	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY (% / bp)	QoQ (% / bp)
GWP (INR bn):							
Retail	31.9	39.1	36.0	47.8	37.1	16.2	(22.4)
Group	3.1	3.9	2.0	3.6	(1.0)	(132.8)	(128.2)
PA	-	-	-	-	-	NM	NM
Travel	-	-	-	-	-	NM	NM
Re-insurance inward	-	-	0.4	-	-	-	-
Total GWP	**35.0**	**43.0**	**38.4**	**51.4**	**36.1**	**3.0**	**(29.8)**
GWP Mix (%)							
Retail	91.1	90.9	93.8	93.0	102.8	1,167.3	981.6
Group	8.9	9.1	5.2	7.0	(2.8)	(1,167.3)	(981.6)
PA	-	-	-	-	-	-	-
Travel	-	-	-	-	-	-	-
Re-insurance inward	-	-	1.0	-	-	-	-
Total	**100**	**100**	**100**	**100**	**100.0**	**-**	**(0.0)**

Source: Company, Nuvama Research

Exhibit 3: Individual agents channel contributes 82.0% (up 200bp YoY/flat QoQ) to GWP

	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY(%/bp)	QoQ(%/bp)
Channel mix (%)							
Individual Agents	80.0	81.0	85.3	82.0	82.0	200bp	0bp
Banca	8	8	5.2	7.0	7.0	(100)bp	0bp
Corporate	5	9	(3.0)	4.0	2.0	(300)bp	(200)bp
Digital	7	2	12.5	7.0	9.0	200bp	200bp
Total	**100**	**100**	**100**	**100**	**100.00**		
Channel mix (INR bn)							
Individual Agents	28.0	34.7	32.4	42.1	29.6	5.6	(29.8)
Banca	2.8	3.4	2.0	3.6	2.5	(9.9)	(29.8)
Corporate	1.8	4.0	(1.1)	2.1	0.7	(58.8)	(64.9)
Digital	2.5	0.9	4.8	3.6	3.2	32.4	(9.8)
Total	**35.0**	**43.0**	**38.0**	**51.4**	**36.1**	**3.0**	**(29.8)**

Source: Company, Nuvama Research

Exhibit 4: Analytical ratios

Analytical ratios	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY(%/bp)	QoQ(%/bp)
Net Retention Ratio (%)	91.2	90.9	93.8	93.8	95.9	469bp	209bp
Net Commission Ratio (%)	13.5	13.8	14.1	15.8	14.7	116bp	(107)bp
EOM to GDPI Ratio (%)	32.2	30.9	31.8	30.0	32.9	71bp	291bp
EOM to NWP Ratio (%)	31.6	30.2	31.8	30.0	32.6	104bp	266bp
Net Incurred Claims to NEP (%)	67.6	72.8	71.4	69.2	69.6	197bp	31bp
Combined Ratio (%)	99.1	103.0	103.3	99.2	102.2	302bp	297bp
Technical Reserves to net premium ratio (%)	286.0	242.0	268.0	219.0	290.0	400bp	7,100bp
Underwriting balance ratio (%)	4.0	(5.2)	(1.3)	(7.2)	1.8	(218)bp	906bp
Operating Profit Ratio (%)	8.9	0.4	4.0	(2.3)	6.3	(255)bp	860bp
Liquid Assets to liabilities ratio (%)	0.2	0.4	0.4	0.4	0.5	31bp	10bp
Net earning ratio (%)	10.1	2.8	6.0	0.0	7.6	(247)bp	758bp
Return on net worth ratio (%)	4.8	1.6	3.1	0.0	3.6	(119)bp	359bp

Source: Company, Nuvama Research

Exhibit 5: Operational metrics

Operational information	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	YoY(%/bp)	QoQ(%/bp)
Number of agents (in mn)	0.7	0.7	0.8	0.8	0.8	9.9	1.8
Sponsored Health Agency Force	0.1	0.1	0.1	0.1	0.1	11.5	1.6
Number of hospitals in network (in actual number)	14.3	14.4	14.3	NA	NA		
Branch Network	887.0	902.0	910.0	913.0	914	3.0	0.1

Source: Company, Nuvama Research

Exhibit 6: Retail health market share declines QoQ to 31%



Source: Company, Nuvama Research

Exhibit 7: Combined ratio increases 301bp YoY to 102.2%



Source: Company, Nuvama Research

Exhibit 8: Distribution mix dominated by agency channel



Source: Company, Nuvama Research

Exhibit 9: Share of retail increases



Source: Company, Nuvama Research

Exhibit 10: Hospital network at 14.4k



Source: Company, Nuvama Research

Exhibit 11: Solvency ratio falls 700bp YoY to 222%



Source: Company, Nuvama Research

Exhibit 12: Change in estimate

	Earlier			Revised			Change (%/bps)		
(INR mn)	**FY26E**	**FY27E**	**FY28E**	**FY26E**	**FY27E**	**FY28E**	**FY26E**	**FY27E**	**FY28E**
Net written premium	173,246	200,185	228,138	171,429	197,277	225,436	(1.0)	(1.5)	(1.2)
Net earned premium	168,422	188,237	213,272	167,293	185,891	210,456	(0.7)	(1.2)	(1.3)
COR (%)	99.3	97.8	97.0	99.7	98.1	97.2	42bps	30bps	20bps
Underwriting profits	(272)	604	2,072	(793)	139	1,503	192.1	(77.0)	(27.4)
Investment book	200,825	226,497	258,336	199,667	224,092	255,400	(0.6)	(1.1)	(1.1)
APAT	8,804	11,764	14,425	8,519	11,457	13,842	(3.2)	(2.6)	(4.0)
EPS	14.8	19.8	24.3	14.3	19.3	23.3	(3.2)	(2.6)	(4.0)
ROE (%)	11.7	13.7	14.6	11.3	13.4	14.1	(36)bp	(29)bp	(46)bp
Target Price (INR)		**500**			**490**			**(2.0)**	
Rating		**BUY**			**BUY**				

Source: Nuvama Research

Q1FY26 conference call: Key highlights

Retail health: GWP grew 18% YoY to INR36.7bn, driven by 25% growth in fresh retail premiums and a renewal persistency of 98% by value. Retail health now contributes 94% of the total portfolio, up from 90% last year.

Market share: STARHEAL maintained its leadership with a 31% market share in the retail health insurance segment even as the base expanded. Fresh retail NOPs (number of policies) grew 8% YoY and overall NOPs rose 5%, indicating balanced volume and value growth.

Digital channel: The digital channel grew rapidly, contributing 20% of new business compared with 12% last year. New digital business grew 73% YoY. Total 70% of business is digital direct, whereas 30% is digital partner.

Agency channel: The agency channel accounted for 82% of total GWP in Q1FY26 and grew 16% YoY. Agent productivity rose 13% and the total agent base expanded by 14,000 to 0.79mn, the highest in the industry. Portability share was consciously kept low at 10% to focus on quality growth.

New products: New products such as Super Star and Health Assure made up 80% of the new business. The Super Star product alone crossed INR10bn in GWP within ten months, making it one of the fastest-growing products in the industry.

Strategic pricing: The company has transitioned to zonal and risk-based pricing models. A discount-based pricing model (e.g. on the Family Health Optima product) has been adopted to balance fairness between claimants and non-claimants. Currently, about 30% of the book has migrated to this pricing model.

Profitability: Q1FY26 IFRS PAT was INR 4.38bn. Investment income rose to INR5.86bn from INR3.88bn in Q1FY25. The company accounted INR2.92bn of MTM gains in its investment income under IFRS accounting. The MTM gain in its investment income has been applied only to non-debt portfolio, which is now 17.5% of its investment book. On the debt book, its MTM gains for the quarter are ~INR2bn, which is not considered under IFRS reporting. Its portfolio has increased allocation to equities and alternative assets (17.5% of AUM), aiming for better long-term yields despite short-term pressure on investment income from falling interest rates.

Loss ratio: Under IFRS, CoR was 99.6% in Q1, up from 99.2% a year ago. Despite past price hikes covering 65% of the portfolio, the claim ratio rose marginally YoY to 69.5%, due to both frequency and severity, though management expects gradual improvement.

Operational efficiency: The IFRS expense ratio reduced by 100bp YoY to 30.1%. STARHEAL highlighted better efficiency through technology investments, disciplined hiring, and improved productivity, especially in the digital and tele-calling segments.

Banca and group business: Bank assurance contributed 7% of GWP, with a shift toward retail and benefit plans (92% of fresh business versus 74% last year). Group business was only 2% of the mix as the company continues to exit large and mid-sized group accounts and focus on SME segments.

Long-term business: New retail policies formed 30% of new business volume and 8% of overall retail book, helping enhance persistency and customer stickiness. Management believes this will lead to improvement in CoR going forward.

FY28 guidance: While the INR25bn IFRS PAT target by FY28 remains intact, assumptions for GWP growth to INR300bn may be moderated due to the exit from corporate business. The PAT goal is likely to be supported 80% by investment income and 20% by underwriting profits.

Reinsurance: Management clarified that it has exited its earlier long-term reinsurance treaty and now only retains the mandatory obligatory cession of around 4–5%. The company explained that this change, along with the adoption of IFRS accounting standards, has influenced the volatility in reinsurance ceded figures and affected how commission expenses are reported.

Underwriting: The company explained that the underwriting profits under IFRS were lower primarily due to the amortisation of acquisition costs related to strong new business growth in previous quarters. Since IFRS recognises revenue and expenses over the policy period (rather than upfront), the full benefit of the premium earned will reflect in subsequent quarters, whereas acquisition costs begin to impact immediately. As a result, the timing mismatch led to lower underwriting profit in the current quarter under IFRS.

Company Description

STARHEAL has one of the largest pan-India distribution networks—913 health insurance branches spread across 26 states and four union territories as on March 31, 2025. Its product suite consists of a range of flexible and comprehensive coverage options, primarily for retail health, group health, personal accident and overseas travel segments.

Star Health & Allied Insurance Co Ltd. is the largest private standalone health insurance company in India headquartered in Chennai. It has been providing innovative services and products in health, personal accident and overseas & domestic travel insurance aligned with the needs of the Indian market. The company also enjoys the largest retail health insurance share based on GWP in the country. In FY25, STARHEAL's retail health market share stood at 32.6%.

Key Risks

- Any significant slowdown in growth.
- Intensifying competition resulting in loss of market share or increased loss/combined ratios
- Exit of key management personnel.
- Any regulation flux that may further stifle easy pricing change.
- Several financial investors and pre-IPO investors, who may look to exit from time to time, hold STARHEALTH's shares. This may result in a constant supply of shares—thereby keeping its price depressed.

Additional Data

Management

MD & CEO	Anand Roy
CFO	Nilesh Kambli
COO	Amitabh Jain
Auditor	T R Chadha & Co LLP and MSKA & Associates

Holdings – Top 10*

	% Holding		% Holding
ICICI Prudentai	4.79	Vanguard group	1.53
ICICI Prudentai	4.60	Government pens	1.28
HDFC AMC	3.97	Norges Bank	1.28
WF Asian smalle	2.48	MIO Star	1.15
Massachusetts I	1.66	WF Asian Reconn	1.00

Latest public data

Recent Company Research

Date	Title	Price	Reco
30-Apr-25	Loss ratios disappoint; *Result Update*	399	Buy
01-Apr-25	Recalibration to improve CoRs; *Company Update*	345	Buy
29-Jan-25	Loss ratios improve mildly; *Result Update*	463	Hold

Recent Sector Research

Date	Name of Co./Sector	Title
16-Jul-25	General Insurance	Jun-25: Growth in core segments slows; *Sector Update*
15-Jul-25	ICICI Lombard GI	Strong investment income drives beat; *Result Update*
07-Jul-25	General Insurance	Jun-25: Growth moderates; *Sector Update*

Rating and Daily Volume Interpretation



Source: Bloomberg, Nuvama research

Rating Rationale & Distribution: Nuvama Research

Rating	Expected absolute returns over 12 months	Rating Distribution
Buy	15%	202
Hold	<15% and >-5%	66
Reduce	<-5%	36

DISCLAIMER

Nuvama Wealth Management Limited (defined as "NWML" or "Research Entity") a company duly incorporated under the Companies Act, 1956 (CIN No L67110MH1993PLC344634) having its Registered office situated at 801- 804, Wing A, Building No. 3, Inspire BKC, G Block, Bandra Kurla Complex, Bandra East, Mumbai – 400 051 is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, Investment Adviser, Research Analyst and other related activities. Name of Compliance/Grievance officer: Mr. Atul Bapna, E-mail address: complianceofficer.nwm@nuvama.com Contact details +91 (22) 6623 3478 Investor Grievance e-mail address- grievance.nwm@nuvama.com

This Report has been prepared by NWML in the capacity of a Research Analyst having SEBI Registration No.INH000011316 and Enlistment no. 5723 with BSE and distributed as per SEBI (Research Analysts) Regulations 2014. This report does not constitute an offer or solicitation for the purchase or sale of any financial instrument or as an official confirmation of any transaction. Securities as defined in clause (h) of section 2 of the Securities Contracts (Regulation) Act, 1956 includes Financial Instruments and Currency Derivatives. The information contained herein is from publicly available data or other sources believed to be reliable. This report is provided for assistance only and is not intended to be and must not alone be taken as the basis for an investment decision. The user assumes the entire risk of any use made of this information. Each recipient of this report should make such investigation as it deems necessary to arrive at an independent evaluation of an investment in Securities referred to in this document (including the merits and risks involved), and should consult his own advisors to determine the merits and risks of such investment. The investment discussed or views expressed may not be suitable for all investors.

This information is strictly confidential and is being furnished to you solely for your information. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NWML and associates, subsidiaries / group companies to any registration or licensing requirements within such jurisdiction. The distribution of this report in certain jurisdictions may be restricted by law, and persons in whose possession this report comes, should observe, any such restrictions. The information given in this report is as of the date of this report and there can be no assurance that future results or events will be consistent with this information. This information is subject to change without any prior notice. NWML reserves the right to make modifications and alterations to this statement as may be required from time to time. NWML or any of its associates / group companies shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NWML is committed to providing independent and transparent recommendation to its clients. Neither NWML nor any of its associates, group companies, directors, employees, agents or representatives shall be liable for any damages whether direct, indirect, special or consequential including loss of revenue or lost profits that may arise from or in connection with the use of the information. Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein. Past performance is not necessarily a guide to future performance .The disclosures of interest statements incorporated in this report are provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. The information provided in these reports remains, unless otherwise stated, the copyright of NWML. All layout, design, original artwork, concepts and other Intellectual Properties, remains the property and copyright of NWML and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the copyright holders.

NWML shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, break down of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of the NWML to present the data. In no event shall NWML be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the NWML through this report.

We offer our research services to clients as well as our prospects. Though this report is disseminated to all the customers simultaneously, not all customers may receive this report at the same time. We will not treat recipients as customers by virtue of their receiving this report.

NWML and its associates, officer, directors, and employees, research analyst (including relatives) worldwide may: (a) from time to time, have long or short positions in, and buy or sell the Securities, mentioned herein or (b) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company/company(ies) discussed herein or act as advisor or lender/borrower to such company(ies) or have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance. (c) NWML may have proprietary long/short position in the above mentioned scrip(s) and therefore should be considered as interested. (d) The views provided herein are general in nature and do not consider risk appetite or investment objective of any particular investor; readers are requested to take independent professional advice before investing. This should not be construed as invitation or solicitation to do business with NWML (e) Registration granted by SEBI and certification from NISM in no way guarantee performance of NWML or provide any assurance of returns to investors and clients.

NWML or its associates may have received compensation from the subject company in the past 12 months. NWML or its associates may have managed or co-managed public offering of securities for the subject company in the past 12 months. NWML or its associates may have received compensation for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. NWML or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Research analyst or his/her relative or NWML's associates may have financial interest in the subject company. NWML and/or its Group Companies, their Directors, affiliates and/or employees may have interests/ positions, financial or otherwise in the Securities/Currencies and other investment products mentioned in this report. NWML, its associates, research analyst and his/her relative may have other potential/material conflict of interest with respect to any recommendation and related information and opinions at the time of publication of research report or at the time of public appearance.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (i) exchange rates can be volatile and are subject to large fluctuations; (ii) the value of currencies may be affected by numerous market factors, including world and national economic, political and regulatory events, events in equity and debt markets and changes in interest rates; and (iii) currencies may be subject to devaluation or government imposed exchange controls which could affect the value of the currency. Investors in securities such as ADRs and Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Research analyst has served as an officer, director or employee of subject Company: No

NWML has financial interest in the subject companies: No

NWML's Associates may have actual / beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report.

Research analyst or his/her relative has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

NWML has actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of research report: No

Subject company may have been client during twelve months preceding the date of distribution of the research report.

There were no instances of non-compliance by NWML on any matter related to the capital markets, resulting in significant and material disciplinary action during the last three years.
A graph of daily closing prices of the securities is also available at www.nseindia.com

Analyst Certification:
The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Additional Disclaimers

Disclaimer for U.S. Persons
This research report is a product of NWML, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by NWML only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, NWML has entered into an agreement with a U.S. registered broker-dealer, Nuvama Financial Services Inc. (formerly Edelweiss Financial Services Inc.) ("NFSI"). Transactions in securities discussed in this research report should be effected through NFSI.

Disclaimer for U.K. Persons
The contents of this research report have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 ("FSMA").

In the United Kingdom, this research report is being distributed only to and is directed only at (a) persons who have professional experience in matters relating to investments falling within Article 19(5) of the FSMA (Financial Promotion) Order 2005 (the “Order”); (b) persons falling within Article 49(2)(a) to (d) of the Order (including high net worth companies and unincorporated associations); and (c) any other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as “relevant persons”).

This research report must not be acted on or relied on by persons who are not relevant persons. Any investment or investment activity to which this research report relates is available only to relevant persons and will be engaged in only with relevant persons. Any person who is not a relevant person should not act or rely on this research report or any of its contents. This research report must not be distributed, published, reproduced or disclosed (in whole or in part) by recipients to any other person.

Disclaimer for Canadian Persons
This research report is a product of NWML, which is the employer of the research analysts who have prepared the research report. The research analysts preparing the research report are resident outside the Canada and are not associated persons of any Canadian registered adviser and/or dealer and, therefore, the analysts are not subject to supervision by a Canadian registered adviser and/or dealer, and are not required to satisfy the regulatory licensing requirements of the Ontario Securities Commission, other Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and are not required to otherwise comply with Canadian rules or regulations regarding, among other things, the research analysts' business or relationship with a subject company or trading of securities by a research analyst.

This report is intended for distribution by NWML only to "Permitted Clients" (as defined in National Instrument 31-103 ("NI 31-103")) who are resident in the Province of Ontario, Canada (an "Ontario Permitted Client"). If the recipient of this report is not an Ontario Permitted Client, as specified above, then the recipient should not act upon this report and should return the report to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any Canadian person.

NWML is relying on an exemption from the adviser and/or dealer registration requirements under NI 31-103 available to certain international advisers and/or dealers. Please be advised that (i) NWML is not registered in the Province of Ontario to trade in securities nor is it registered in the Province of Ontario to provide advice with respect to securities; (ii) NWML's head office or principal place of business is located in India; (iii) all or substantially all of NWML's assets may be situated outside of Canada; (iv) there may be difficulty enforcing legal rights against NWML because of the above; and (v) the name and address of the NWML's agent for service of process in the Province of Ontario is: Bamac Services Inc., 181 Bay Street, Suite 2100, Toronto, Ontario M5J 2T3 Canada.

Disclaimer for Singapore Persons
In Singapore, this report is being distributed by Nuvama Investment Advisors Private Limited (NIAPL) (Previously Edelweiss Investment Advisors Private Limited ("EIAPL")) (Co. Reg. No. 201016306H) which is a holder of a capital markets services license and an exempt financial adviser in Singapore and (ii) solely to persons who qualify as "institutional investors" or "accredited investors" as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Pursuant to regulations 33, 34, 35 and 36 of the Financial Advisers Regulations ("FAR"), sections 25, 27 and 36 of the Financial Advisers Act, Chapter 110 of Singapore shall not apply to NIAPL when providing any financial advisory services to an accredited investor (as defined in regulation 36 of the FAR. Persons in Singapore should contact NIAPL in respect of any matter arising from, or in connection with this publication/communication. This report is not suitable for private investors.

Disclaimer for Hong Kong persons
This report is distributed in Hong Kong by Nuvama Investment Advisors (Hong Kong) Private Limited (NIAHK) (Previously Edelweiss Securities (Hong Kong) Private Limited (ESHK)), a licensed corporation (BOM -874) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to Section 116(1) of the Securities and Futures Ordinance “SFO”. This report is intended for distribution only to “Professional Investors” as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors.” Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The report also does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of any individual recipients. The Indian Analyst(s) who compile this report is/are not located in Hong Kong and is/are not licensed to carry on regulated activities in Hong Kong and does not / do not hold themselves out as being able to do so.

INVESTMENT IN SECURITIES MARKET ARE SUBJECT TO MARKET RISKS. READ ALL THE RELATED DOCUMENTS CAREFULLY BEFORE INVESTING.

Abneesh Roy
Head of Research Committee
Abneesh.Roy@nuvama.com

ABNEESH KUMAR ROY

Digitally signed by ABNEESH KUMAR ROY
DN: c=IN, o=Personal, pseudonym=Msg9fxP7wyHcUJj8U9hqnElitaBp7XDX, 2.5.4.20=e648fc28137c6fa4c0e6296c524ee518d54fd4f7ba4be4d07cb750c531c68e2c, postalCode=400098, st=Maharashtra, serialNumber=7370c9de10fb28bbf7cbc6f71afe3cfe848fa7245a8d681629dc3093fb2a8ea9, cn=ABNEESH KUMAR ROY
Date: 2025.07.30 13:31:53 +05'30'
Adobe Acrobat version: 2025.001.20577